SCHEMBL5369908

SCHEMBL5369908

COc1cc(O)ccc1C=C1C(=O)Nc2ccc(S(=O)(=O)Nc3ccc(C(F)(F)F)cc3)cc21

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MOGAT2 Q3SYC2 3/20 0.52
MEN1 O00255 1/20 0.51
ALOX15 P16050 1/20 0.51
MAPK1 P28482 1/20 0.51
KMT2A Q03164 1/20 0.51
MGAT2 Q10469 2/20 0.49
MDM2 Q00987 2/20 0.46
BRD4 O60885 2/20 0.44
NTRK1 P04629 3/20 0.43
SYK P43405 2/20 0.43
NTRK3 Q16288 2/20 0.42
NTRK2 Q16620 2/20 0.42
FCER2 P06734 1/20 0.42
RET P07949 1/20 0.42
GSK3B P49841 3/20 0.42
CYP1A1 P04798 1/20 0.41
CYP1B1 Q16678 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5363913 0.91 MDM2 (0.59) MOGAT2MEN1ALOX15MAPK1KMT2A
SCHEMBL5368257 0.90 MEN1 (0.57) MOGAT2MEN1ALOX15MAPK1KMT2A
SCHEMBL7137732 0.89 MOGAT2 (0.55) MOGAT2MEN1ALOX15MAPK1KMT2A
SCHEMBL5361444 0.89 MOGAT2 (0.54) MOGAT2MEN1ALOX15MAPK1KMT2A
SCHEMBL5359068 0.88 MOGAT2 (0.51) MOGAT2MEN1ALOX15MAPK1KMT2A
SCHEMBL5377343 0.88 MOGAT2 (0.52) MOGAT2MEN1ALOX15MAPK1KMT2A
SCHEMBL5367388 0.87 MOGAT2 (0.51) MOGAT2MEN1ALOX15MAPK1KMT2A
SCHEMBL5367311 0.87 MEN1 (0.54) MOGAT2MEN1ALOX15MAPK1KMT2A
SCHEMBL7133813 0.87 MOGAT2 (0.52) MOGAT2MEN1ALOX15MAPK1KMT2A
SCHEMBL5357716 0.87 MOGAT2 (0.54) MOGAT2MEN1ALOX15MAPK1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK MOGAT2 1159/4885MEN1 3855/4885ALOX15 748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.